Verastem (Verastem) Cash-to-Debt : 3.30 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Verastem Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Verastem's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.30.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Verastem could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Verastem's Cash-to-Debt or its related term are showing as below:

VSTM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.7 Med: 6.06 Max: No Debt
Current: 3.3

During the past 13 years, Verastem's highest Cash to Debt Ratio was No Debt. The lowest was 0.70. And the median was 6.06.

VSTM's Cash-to-Debt is ranked worse than
60.69% of 1539 companies
in the Biotechnology industry
Industry Median: 6.54 vs VSTM: 3.30

Verastem Cash-to-Debt Historical Data

The historical data trend for Verastem's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Verastem Cash-to-Debt Chart

Verastem Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.70

6.27

31.53

3.25

3.30

Verastem Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															3.25	2.59	4.31	3.94	3.30

Competitive Comparison of Verastem's Cash-to-Debt

For the Biotechnology subindustry, Verastem's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verastem's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Verastem's Cash-to-Debt falls into.

Verastem Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Verastem's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	137.129	/	(0.941	+	40.616)
	=	3.30

Verastem's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	137.129	/	(0.941	+	40.616)
	=	3.30

Verastem (NAS:VSTM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Verastem Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Verastem's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Verastem (Verastem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (NAS:VSTM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

2VS:Germany

Address

117 Kendrick Street, Suite 500, Needham, MA, USA, 02494

Website

https://www.verastem.com

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Executives

Robert E. Gagnon	officer: Chief Financial Officer	C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Daniel Calkins	officer: Vice President of Finance	C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Brian M Stuglik	director	C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Dan Paterson	officer: Chief Operating Officer	215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Karin Anna Tollefson	director	C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Anil Kapur	director	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104